Teva's UZEDY® Sales Surge 43% YoY; Medincell Royalties and Milestones in Focus
Event summary
- UZEDY® U.S. net sales hit $77M in Q2 2026, up 43% YoY.
- Teva raised its 2026 revenue outlook for UZEDY® to $270M–$290M from $250M–$280M.
- U.S. prescriptions normalized into months of therapy increased 63% YoY, driven by prescriber expansion (800+ new prescribers/month).
- Medincell eligible for up to $105M in commercial milestone payments tied to UZEDY® sales thresholds.
The big picture
Teva’s strong performance with UZEDY® underscores the growing demand for long-acting injectables in mental health treatment. The partnership with Medincell, leveraging its BEPO® technology (licensed as SteadyTeq™), highlights a strategic shift toward sustained-release formulations. The upcoming regulatory decision on olanzapine LAI could further solidify Teva’s position in this high-growth segment.
What we're watching
- Regulatory Approval
- Whether Teva’s once-monthly olanzapine LAI secures FDA approval in Q4 2026, expanding its long-acting injectable portfolio.
- Revenue Momentum
- The pace at which UZEDY® maintains its 43% YoY growth trajectory amid competitive pressures in schizophrenia and bipolar disorder treatments.
- Milestone Payments
- How quickly Medincell achieves the sales thresholds required to unlock up to $105M in commercial milestone payments from Teva.
Related topics